by Louisiana State University CB-103 shows synergy with paclitaxel and fulvestrant in breast cancer cell lines. TNBC (HCC1187) and ER+ BC (MCF-7) cells were treated with combinations of CB-103 (150 nM–10 μM) with paclitaxel or fulvestrant (75 nM–20 μM) and cell viability was measured after 72 h of treatment. Synergy between CB-103 and paclitaxel or fulvestrant...
by Delthia Ricks, Medical Xpress Therapeutic inhibition of VEGF binding to NRP2 activates anti-tumor immunity in a syngeneic model of prostate cancer that is resistant to aPD-L1 therapy. (A) Shown is quantification of tumor volume in C57BL/6J mice injected with TRAMP-C2 cells and treated with either IgG control or aPD-L1 antibody. Error bars represent SEM....
Over-diagnosis, the detection of cancer with mammography that would not become clinically evident in the woman’s remaining lifetime, can lead to unnecessary treatments and stress, researchers say. Researchers designed the study to clarify the risk of breast cancer over-diagnosis using contemporary screening technology in the US. The findings in the Annals of Internal Medicine should inform decision-making about mammography screening...
SWOG CANCER RESEARCH NETWORK PORTLAND, OR – Researchers with the SWOG Cancer Research Network have found that patients with metastatic hormone receptor-positive breast cancer who have low activity levels of the enzyme sTK1 in their blood serum at the start of anti-estrogen treatment live longer and go longer without their disease progressing than patients with...
by Georgia State University Credit: CC0 Public Domain ProAgio, a drug developed by Georgia State University biology professor Zhi-Ren Liu and his team, is effective at treating pancreatic cancer and prolonging survival in mice, according to a study published in the journal Cellular and Molecular Gastroenterology and Hepatology. A second study, published in the Journal of Experimental...
